Circio Holding ASA (CRNA.OL) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Norway · ISIN NO0013033795

Price
9.30 NOK
Market cap
2.71 bn NOK
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
367.49 %
Return on assets (ROA)
-426.80 %

Circio Holding ASA financials

Fiscal year20242025
Revenue0.00 NOK0.00 NOK
Operating income-42.49 m NOK-41.05 m NOK
EBIT-42.49 m NOK-45.74 m NOK
Net income57.52 m NOK-45.91 m NOK
Diluted EPS – continuing operations0.79 NOK-0.31 NOK

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Circio Holding ASA

Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.